Evaluating cost benefits of combination therapies for advanced melanoma
Background: Although a number of monoimmunotherapies and targeted therapies are available to treat BRAF+ advanced melanoma, response rates remain relatively low in the range of 22–53% with progression-free survival (PFS) in the range of 4.8–8.8 months. Recently, combination targeted therapies have i...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BioExcel Publishing Ltd
2016-07-01
|
| Series: | Drugs in Context |
| Subjects: | |
| Online Access: | http://www.drugsincontext.com/evaluating-cost-benefits-of-combination-therapies-for-advanced-melanoma/ |